1.
[Effects of Pre-Transplant CONUT and Post-Transplant MRD on Prognosis of Patients with Multiple Myeloma after Auto-HSCT]
Xiong, Y. Y., Zhou, Q., Chen, L., Yu, W., Zhang, H. B., Chen, J. B.
Zhongguo shi yan xue ye xue za zhi. 2024;32(1):146-154
Abstract
OBJECTIVE To explore the effects of pre-transplant controlling nutritional status (CONUT) and post-transplant minimal residual disease (MRD) on prognosis of patients with multiple myeloma (MM) after autologous hematopoietic stem cell transplantation (auto-HSCT). METHODS The clinical data of 79 patients who received auto-HSCT from 2011 to 2020 in The First Affiliated Hospital of Chongqing Medical University were retrospectively analyzed. The patients were divided into Low-CONUT group (n=62) and High-CONUT group (n=17) according to whether the CONUT score was less than 5. The differences in clinical features, hematopoietic reconstruction, adverse reactions, efficacy and survival between the two groups were compared. In addition, the prognostic risk factors were analyzed and verified by time-dependent ROC curve. RESULTS The proportions of male patients and bone marrow plasma cells>30% at initial diagnosis in High-CONUT group were both higher than those in Low-CONUT group (both P <0.05). While, there were no significant differences in hematopoietic reconstruction and adverse reactions (>grade 2) between the two groups. The complete response (CR) rate and CR+very good partial response (VGPR) rate before transplantation in Low-CONUT group were both significantly higher than those in High-CONUT group (both P <0.05). After 3 months of transplantation, the CR+VGPR rate still remained an advantage in Low-CONUT group compared with High-CONUT group (P <0.01), but CR rate did not(P >0.05). The overall survival (OS) and progression-free survival (PFS) in Low-CONUT group were both superior to those in High-CONUT group (both P <0.05). Low CONUT score (0-4) before transplantation and negative MRD at 6 months after transplantation were favorable factors affecting OS and PFS (both P <0.05), while the International Myeloma Working Group (IMWG) high-risk at initial diagnosis and lactate dehydrogenase (LDH) level>250 U/L before transplantation were only risk factors for PFS (both P <0.05). Time-dependent ROC curve analysis showed that pre-transplant CONUT score and MRD status at 6 months after transplantation could independently or jointly predict 1- and 2-year OS and PFS, and the combined prediction was more effective. CONCLUSION The combination of pre-transplant CONUT and post-transplant MRD can better predict the prognosis of MM patients.
2.
Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplant
Kuypers, J., Simmance, N., Quach, H., Hastie, K., Kiss, N.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2022
Abstract
PURPOSE Malnutrition is associated with worse outcomes post-haematopoietic stem cell transplantation, with nutrition support recommended for people who are malnourished or have prolonged inadequate energy intake. We investigated associations between nutritional status, nutrition support type and clinical outcomes in adults with multiple myeloma post stem cell transplantation. METHODS Medical records (2015-2020) were reviewed to retrieve demographics, anthropometry, dietary data, nutrition support type (enteral/oral versus parenteral), and clinical outcomes (engraftment time, infection, length of stay, weight changes). Relationships were examined using linear regression modelling and Fisher's exact test. RESULTS One hundred thirteen participants were included (61% male; median age 62 years). Fifteen participants (13%) received parenteral and 98 (87%) received enteral/oral nutrition support. Parenteral nutrition was associated with shorter platelet engraftment time by 2.7 days (p = 0.036) and a longer hospital stay by 6.1 days (p < 0.001). Nutrition support was not associated with neutrophil engraftment time (p = 0.365). Inadequate energy intake for ≥ 7 days was not associated with any clinical outcomes (p > 0.05). CONCLUSIONS Participants who received parenteral nutrition reached platelet engraftment sooner but were in hospital longer. Inadequate energy intake for ≥ 7 days did not impact clinical outcomes. Multi-site prospective studies are warranted to confirm results.
3.
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naive lymphocytes and prevents TTV reactivation
Iovino, L., Mazziotta, F., Carulli, G., Guerrini, F., Morganti, R., Mazzotti, V., Maggi, F., Macera, L., Orciuolo, E., Buda, G., et al
Leukemia research. 2018;70:20-24
Abstract
INTRODUCTION Zinc plays an important role in thymic function and immune homeostasis. We performed a prospective clinical trial using a high-dose zinc oral supplementation to improve the immune reconstitution after hematopoietic stem cell transplant (HSCT). PATIENTS AND METHODS We enrolled 18 patients undergoing autologous HSCT for multiple myeloma. Nine patients were randomized to receive only a standard antimicrobial prophylaxis; whereas, nine patients received in addition 150mg/day of zinc from day +5 to day +100 after transplant. RESULTS CD4+ naive lymphocytes and TRECs showed a significant increase from day +30 until day +100 only in the zinc-treated group. Moreover, the load of Torquetenovirus, a harmless virus that replicates in course of immunedepression, increased at day +100 only in the control group. No severe adverse events were reported during the zinc consumption. CONCLUSION First data from the ZENITH trial suggest that high-dose zinc supplementation is safe and may enhance the thymic reconstitution after HSCT. Registered: http://Clinicaltrials.gov (NCT03159845); and EUDRACT 2014-28 004499-47.